Bladder Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | RemeGen, UroGen, Asieris, Pfizer, Roche, Protara, Emtora

Posted on
by

Bladder Cancer Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | RemeGen, UroGen, Asieris, Pfizer, Roche, Protara, Emtora
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Bladder Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Bladder Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Bladder Cancer Market. 

The Bladder Cancer Pipeline report embraces in-depth commercial, regulatory, and Bladder Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Bladder Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Bladder Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Bladder Cancer treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Bladder Cancer therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Bladder Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Bladder Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Bladder Cancer therapeutic market.

 

Bladder Cancer Therapeutics Landscape

Different types of treatment are available for bladder cancer. The treatment plan is based on the type, stage, and grade of the cancer, and overall health. Some of the treatments involved are as follows:

  • Systemic chemotherapy: systemic chemotherapy for bladder cancer is when chemotherapy drugs are injected into a vein. drugs that may be used to treat bladder cancer include carboplatin, cisplatin, doxorubicin, fluorouracil, among others.

  • Intravesical chemotherapy: For bladder cancer, chemotherapy may be intravesical, which means it is put into the bladder through a tube inserted into the urethra. Intravesical treatments flush the bladder with drugs that kill cancer cells that remain after surgery. Mitomycin and gemcitabine are two chemotherapy drugs given as intravesical chemotherapy to treat bladder cancer.

  • Immunotherapy: Systemic immunotherapy drugs used to treat urothelial cancer (a type of bladder cancer) include avalumab, nivolumab, and pembrolizumab. These drugs work in more than one way to kill cancer cells. Moreover, BCG (bacillus Calmette-Guérin) is an intravesical immunotherapy drug used to treat bladder cancer. BCG is given in a solution that is placed directly into the bladder using a catheter (thin tube).

There are approx. 100+ key companies developing therapies for Bladder cancer. Currently, CG Oncology is leading the therapeutics market with its Bladder cancer drug candidates in the most advanced stage of clinical development.

Bladder Cancer Companies Actively Working in the Therapeutic Market Include:

CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, Linton Pharm Co., Ltd., Nektar Therapeutics, Hamlet Pharma AB, Asieris Pharmaceuticals, Wuhan Binhui Biotechnology, Pfizer, Taizhou Hanzhong biomedical co. LTD, Hoffmann-La Roche, Protara Therapeutics, AstraZeneca, CicloMed LLC, enGene, Inc., Emtora Biosciences, Qilu Pharmaceutical Co., Ltd., Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, Lindis Biotech, Incyte Corporation, Eli Lilly and Company, Daiichi Sankyo, Nektar Therapeutics, Pieris Pharmaceuticals, Inc., Istari Oncology, Inc., BeiGene, Vyriad, Inc., Adlai Nortye Biopharma Co., Ltd., Kyowa Kirin, Inc., Infinity Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Fusion Pharmaceuticals Inc., GI Innovation, Inc., SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, and many others.

Emerging and Marketed Bladder Cancer Drugs Covered in the Report Include:

  • CG0070: CG Oncology

  • N-803: ImmunityBio

  • UGN-102: UroGen

  • Trilaciclib: G1 Therapeutics

  • APL-1202: Asieris Pharmaceuticals

  • TAR-200: Janssen Research & Development, LLC

  • HX008: Lepu Biopharma Co., Ltd.

  • Futibatinib: Taiho Oncology, Inc.

  • TLD-1433: Theralase Technologies Inc.

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Bladder Cancer Companies Working in the Market @ 

https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight

Analysis of Emerging Bladder Cancer Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

Learn How the Bladder Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Bladder Cancer Treatment Patterns

4. Bladder Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Bladder Cancer Late Stage Products (Phase-III)

7. Bladder Cancer Mid-Stage Products (Phase-II)

8. Bladder Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Bladder Cancer Discontinued Products

13. Bladder Cancer Product Profiles

14. Major Bladder Cancer Companies in the Market

15. Key Products in the Bladder Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Bladder Cancer Unmet Needs

18. Bladder Cancer Future Perspectives

19. Bladder Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report@ 

https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Von Willebrand Disease (VWD) Market

“Von Willebrand Disease (VWD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Von Willebrand Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Von Willebrand Disease market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology